Skip to Content

Requip XL (ropinirole) Disease Interactions

There are 6 disease interactions with Requip XL (ropinirole):

Major

Dopamine agonists (Includes Requip XL) ↔ hypotension

Severe Potential Hazard, High plausibility. Applies to: Hypotension

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.

References

  1. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
  3. Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol 30 (1990): 194-9
  4. "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.
  5. Hoehn MM "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol 32 (1975): 50-1
  6. "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
View all 6 references
Major

Dopaminergic antiparkinson agents (Includes Requip XL) ↔ psychosis

Severe Potential Hazard, Moderate plausibility. Applies to: Psychosis

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.

Major

Ropinirole (Includes Requip XL) ↔ neuroleptic malignant syndrome

Severe Potential Hazard, Low plausibility. Applies to: Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole, however, the syndrome has rarely been precipitated by rapid dosage reduction, abrupt discontinuation, or changes in other dopamine agonist therapy.

References

  1. "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.
Moderate

Ropinirole (Includes Requip XL) ↔ cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease

The trials of ropinirole excluded patients with significant cardiovascular disease, hence patients with cardiovascular conditions should be treated with caution.

References

  1. "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.
Moderate

Ropinirole (Includes Requip XL) ↔ hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole may be increased and the elimination half-life prolonged in these patients. Therapy with ropinirole should be administered cautiously in patients with hepatic impairment, and dosages titrated according to patient parameters and clinical tolerability.

References

  1. "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.
  2. Bloomer JC, Clarke SE, Chenery RJ "In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole." Drug Metab Dispos 25 (1997): 840-4
Moderate

Ropinirole (Includes Requip XL) ↔ renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Ropinirole is primarily eliminated by the kidney. Less than 10% of ropinirole is excreted unchanged in the urine. No dose adjustment is necessary in patients with moderate renal impairment (CrCl 30 to 50 mL/min). For patients with end-stage renal disease on hemodialysis, a reduced maximum dose is recommended.

References

  1. "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.

Requip XL (ropinirole) drug interactions

There are 652 drug interactions with Requip XL (ropinirole)

Requip XL (ropinirole) alcohol/food interactions

There are 2 alcohol/food interactions with Requip XL (ropinirole)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide